Penumbra, Inc. Q3 2025 Earnings Recap

PEN Q3 2025 November 7, 2025

Get alerts when PEN reports next quarter

Penumbra reported strong third-quarter results for 2025, achieving $354.7 million in revenue driven by robust growth across its U.S. thrombectomy and embolization franchises, highlighting its competitive positioning and successful product innovation.

Earnings Per Share Beat

$0.97 vs $0.93 est.

+4.4% surprise

Revenue Beat

354685000 vs 340951385 est.

+4.0% surprise

Market Reaction

1-Day +0.6%

5-Day +5.93%

30-Day +8.73%

See PEN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue increased by 17.8% year-over-year, with U.S. revenue growing 21.5% to $275 million.
The VTE franchise achieved remarkable 34% year-over-year growth, affirming its market leadership.
Gross margin expanded to 67.8%, with operating income at $48.8 million (13.8% of revenue), and future margins are projected to exceed 70%.
FDA clearance for breakthrough products Lightning Bolt 16 and Lightning Flash 3.0 enhances Penumbra's advanced CAVT device portfolio.
The integration of a dedicated embolization sales team has resulted in a 21.2% sequential revenue increase in this segment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PEN on AllInvestView.